Abstract |
This report outlines the structure scheme and development of a new antimalarial drug pyronaridine, which was synthesized from either 2-aminopyridine or pyridine. A series of in vivo and in vitro experimental studies and the assessment of toxicity revealed pyronaridine to be a promising agent against erythrocytic stage of malaria parasites. It exhibited low toxicity and had no cross-resistance to chloroquine. Clinical administration in malaria cases showed high efficacy and mild side-effects. In order to retard the development of resistance of Plasmodium falciparum to pyronaridine, a combination of pyronaridine/ sulfadoxine/pyrimethamine was used in the treatment of chloroquine-resistant falciparum malaria in Hainan Province. Further in vivo test was carried out to monitor the sensitivity of P. falciparum to this combined formula for 5 years (1986-1990) in Diaoluo area where chloquine-resistant falciparum malaria was prevalent. Drug resistance was not demonstrated in this field study.
|
Authors | C Chen, X Zheng |
Journal | Biomedical and environmental sciences : BES
(Biomed Environ Sci)
Vol. 5
Issue 2
Pg. 149-60
(Jun 1992)
ISSN: 0895-3988 [Print] China |
PMID | 1642789
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Review)
|
Chemical References |
- Antimalarials
- Naphthyridines
- Sulfadoxine
- Chloroquine
- pyronaridine
- Pyrimethamine
|
Topics |
- Administration, Oral
- Animals
- Antimalarials
(administration & dosage, adverse effects, chemistry)
- Cardiovascular System
(drug effects)
- Chloroquine
(therapeutic use)
- Dogs
- Drug Evaluation
- Drug Evaluation, Preclinical
- Drug Resistance
- Drug Therapy, Combination
- Haplorhini
- Humans
- Injections, Intramuscular
- Lethal Dose 50
- Malaria, Falciparum
(drug therapy)
- Mice
- Naphthyridines
(administration & dosage, adverse effects, chemistry)
- Pyrimethamine
(administration & dosage)
- Rabbits
- Sulfadoxine
(administration & dosage)
|